- BNF:
- Immune System & Mailgnant Disease
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
RED:
- Acute myeloid leukaemia, newly diagnosed do novo or secondary in adults of all ages who are not suitable for standard induction chemotherapy. (Decision date - Sept 2016).
DO NOT PRESCRIBE (DNP):
- NICE TA270: Decitabine for the treatment of acute myeloid leukaemia. (Terminated appraisal). (Decision date - January 2013).
- NICE TA548: Decitabine for untreated acute myeloid leukaemia. (Terminated appraisal). (Decision date - January 2019).
NHS England drug. To be used in line with NHSE commissioning intentions.
Do Not Prescribe (DNP) Drug Classifications
- 4: Have a lack of data on cost-effectiveness compared with standard therapy
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
